Please provide your email address to receive an email when new articles are posted on . The offspring of women who used modafinil or armodafinil during pregnancy had a higher risk of major congenital ...
TORONTO, Jan. 9, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired the ...
How to buy armodafinil cheap overnight online Armodafinil is also manufactured by the same company as Modalert Sun Pharma and available here as Waklert. Compared to Modafinil, Armodafinil has a longer ...
Serious rash, including Stevens-Johnson Syndrome (SJS), requiring hospitalization and discontinuation of treatment, has been reported in adults in association with the use of armodafinil and modafinil ...
Cephalon, Inc. (Nasdaq: CEPH) today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application ...
Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...
Company Expects FDA Decision by End of First Quarter 2010 FRAZER, Pa., Dec. 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S ...
Nuvigil launched for excessive sleepiness Nuvigil (armodafinil tablets) is expected to be made available by Cephalon on June 1, 2009. Nuvigil (armodafinil tablets) is expected to be made available by ...
Cephalon won't let Provigil go gently into that post-patent night. Already, the drugmaker has readied its follow-up: Nuvigil, an extended release form of the stay-awake drug. Like Effexor and Effexor ...
Cephalon is facing a delay in securing approval for Nuvigil, its new treatment for excessive sleepiness associated with narcolepsy and other disorders in the USA, after the Food and Drug ...
FRAZER, Pa., March 29, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback